In last trading session, PDS Biotechnology Corporation (NASDAQ:PDSB) saw 0.52 million shares changing hands with its beta currently measuring 1.26. Company’s recent per share price level of $1.42 trading at $0.07 or 5.19% at ring of the bell on the day assigns it a market valuation of $64.91M. That closing price of PDSB’s stock is at a discount of -211.27% from its 52-week high price of $4.42 and is indicating a premium of 40.14% from its 52-week low price of $0.85. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.24 million shares which gives us an average trading volume of 618.48K if we extend that period to 3-months.
For PDS Biotechnology Corporation (PDSB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
PDS Biotechnology Corporation (NASDAQ:PDSB) trade information
Upright in the green during last session for gaining 5.19%, in the last five days PDSB remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $1.42 price level, adding 2.07% to its value on the day. PDS Biotechnology Corporation’s shares saw a change of -12.88% in year-to-date performance and have moved 18.33% in past 5-day. PDS Biotechnology Corporation (NASDAQ:PDSB) showed a performance of 36.54% in past 30-days. Number of shares sold short was 2.97 million shares which calculate 11.14 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 9 to the stock, which implies a rise of 84.22% to its current value. Analysts have been projecting 9 as a low price target for the stock while placing it at a high target of 9. It follows that stock’s current price would drop -533.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of -533.8% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.42% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 11.00% while estimates for its earnings growth in next 5 years are of 4.75%.
PDS Biotechnology Corporation (NASDAQ:PDSB)’s Major holders
Insiders are in possession of 3.09% of company’s total shares while institution are holding 17.96 percent of that, with stock having share float percentage of 18.53%. Investors also watch the number of corporate investors in a company very closely, which is 17.96% institutions for PDS Biotechnology Corporation that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at PDSB for having 1.41 million shares of worth $4.13 million. And as of 2024-06-30, it was holding 3.8395 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 0.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.3271 of outstanding shares, having a total worth of $1.43 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.02 shares of worth $1.44 million or 2.23% of the total outstanding shares. The later fund manager was in possession of 456.79 shares on Dec 31, 2024 , making its stake of worth around $0.65 million in the company or a holder of 1.00% of company’s stock.
